ATE68976T1 - Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen. - Google Patents

Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen.

Info

Publication number
ATE68976T1
ATE68976T1 AT87907713T AT87907713T ATE68976T1 AT E68976 T1 ATE68976 T1 AT E68976T1 AT 87907713 T AT87907713 T AT 87907713T AT 87907713 T AT87907713 T AT 87907713T AT E68976 T1 ATE68976 T1 AT E68976T1
Authority
AT
Austria
Prior art keywords
solubilization
proteins
pharmaceutical compositions
solubilizing agent
protein
Prior art date
Application number
AT87907713T
Other languages
English (en)
Inventor
Lois Aldwin
Danute E Nitecki
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of ATE68976T1 publication Critical patent/ATE68976T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT87907713T 1986-11-14 1987-11-10 Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen. ATE68976T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/931,197 US4894226A (en) 1986-11-14 1986-11-14 Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
PCT/US1987/002930 WO1988003412A1 (en) 1986-11-14 1987-11-10 Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
EP87907713A EP0305409B1 (de) 1986-11-14 1987-11-10 Solubilisierung von proteinen für pharmazeutsche zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE68976T1 true ATE68976T1 (de) 1991-11-15

Family

ID=25460367

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87907713T ATE68976T1 (de) 1986-11-14 1987-11-10 Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen.

Country Status (7)

Country Link
US (1) US4894226A (de)
EP (1) EP0305409B1 (de)
AT (1) ATE68976T1 (de)
AU (1) AU626518B2 (de)
CA (1) CA1305051C (de)
DE (1) DE3774274D1 (de)
WO (1) WO1988003412A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994385A (en) * 1987-10-30 1991-02-19 Abbott Laboratories Heterobifunctional coupling agents
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
AU657483B2 (en) * 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
CA2086527A1 (en) * 1990-07-26 1992-01-27 Samuel J. Tremont Polymeric drug delivery system
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US7449186B1 (en) * 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
DE69126124T2 (de) * 1990-09-28 1997-08-28 Neorx Corp Polymere träger zur freisetzung kovalent gebundener wirkstoffe
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR960705579A (ko) * 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5686444A (en) * 1995-04-05 1997-11-11 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
EP2599503B1 (de) 1998-10-16 2017-05-17 Biogen MA Inc. Polymerkonjugate von Interferon-Beta-1A und Verwendungen dafür
DK1121382T3 (da) 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
CN1376164A (zh) * 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
ATE464062T1 (de) * 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
SK3102004A3 (sk) * 2002-01-18 2005-01-03 Biogen Idec MA Inc. Polyalkylénglykol s časťou na konjugáciu biologicky aktívnej zlúčeniny
ATE424215T1 (de) 2003-01-08 2009-03-15 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
SI1694360T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje avtoimunskih in vnetnih bolezni in zavrnitve transplantata organa
EP2395099A3 (de) * 2006-05-02 2012-05-16 Allozyne, Inc. Aminosäuresubstituierte Moleküle
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
AU2008250518B2 (en) 2007-05-16 2013-09-12 Ktb Tumorforschungsgesellschaft Mbh Low-viscous anthracycline formulation
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10443026B2 (en) * 2017-12-25 2019-10-15 National Tsing Hua University Polygonal scaffold and manufacturing method thereof, and protein modulator and manufacturing method thereof
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN117241831A (zh) 2021-05-07 2023-12-15 北京大学 水相引发氨基酸n-羧基环内酸酐聚合的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE343210B (de) * 1967-12-20 1972-03-06 Pharmacia Ab
GB1479268A (en) * 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (de) * 1975-05-30 1978-03-15 Battelle Memorial Institute
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
JPS5688794A (en) * 1979-12-19 1981-07-18 Matsushita Electric Ind Co Ltd Immobilization of enzyme
JPS57163318A (en) * 1981-03-31 1982-10-07 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4414147A (en) * 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4716120A (en) * 1983-03-17 1987-12-29 Minnesota Mining And Manufacturing Company Stable allergenic extracts and methods
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (de) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
AU626518B2 (en) 1992-08-06
WO1988003412A1 (en) 1988-05-19
EP0305409B1 (de) 1991-10-30
AU8326487A (en) 1988-06-01
DE3774274D1 (de) 1991-12-05
EP0305409A1 (de) 1989-03-08
CA1305051C (en) 1992-07-14
US4894226A (en) 1990-01-16

Similar Documents

Publication Publication Date Title
ATE68976T1 (de) Solubilisierung von proteinen fuer pharmazeutsche zusammensetzungen.
IE861706L (en) Solubilization of proteins for pharmaceutical compositions¹using polymer conjugation
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
RU94006023A (ru) Физиологически активная композиция на основе лиофилизированных модифицированных полиалкилен оксидом комплексов белка и полипептида с циклодекстрином и способ ее получения
DE69425464D1 (de) Polysaccharidderivat und wirkstoffträger
DE50014571D1 (de) Träger-pharmaka-konjugate
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
PT1017413E (pt) Formulacoes liquidas de interferao (beta)
ATE126523T1 (de) Saccharid-modifizierte, wasserlösliche proteine.
MA26625A1 (fr) Conjugue de proteine hedgehog a activite accrue, procede pour sa production, et son utilisation therapeutique
HUP9900506A2 (hu) Protrombinszármazékok
TR199902575T2 (xx) Peptitler, proteinler ve nükleik asitler için stabil farmasötik uygulama formu.
PT85317A (fr) Procede pour l:obtention d:imunotoxines par couplage d:un anticorps avec une proteine trichosanthine ou trickokirine
BG97123A (bg) Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
DK292584D0 (da) Biologisk aktive konjugater, deres fremstilling og anvendelse
ES2056149T3 (es) Ambliommina, una nueva sustancia activa para la terapia anticoagulante.
AU1477295A (en) Use of azoles as virucidal agents in solutions of biologically active proteins
DE68923613D1 (de) Superoxid-dismutaseanaloge mit neuen bindeeigenschaften.
DE59004814D1 (de) t-PA-Solubilisierung.
FI98891B (fi) Menetelmä vesiliuoksen proteiinipitoisuuden lisäämiseksi
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
ATE210465T1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
SU1400037A1 (ru) Полимерный реагент для ковалентной иммобилизации биологически активных соединений, содержащих свободные аминогруппы
SE9101586D0 (sv) Modified thioredoxin and its use
TR199900933A2 (xx) Etkin, dikenli yapı proteni eşleniği.